Psycheceutical has been granted exclusive license of two major patents that will psychedelic compounds to be administered without any side effects.
Psycheceutical‘s patented delivery systems will enable psychedelics such as psilocybin, ibogaine and ketamine to be administered without side effects and toxicity by bypassing the stomach and the liver.
The delivery systems will enable the administration of psychedelic compounds without passing through the digestive tract, which will improve uptake and minimise harmful side effects, and will also eliminate the hallucinogenic effect of the compounds.
The delivery systems
The first system, the Janus particle solution, which was established following groundbreaking research conducted at the University of Michigan by Professor Dr Anish Tuteja, uses layered nanoparticles that target specific cells and deliver multiple medicines at different times and rates.
Dr Tuteja, who has now joined Psycheceutical as chief science officer, commented: “The Janus particle technology has immense potential to transform the delivery of psychedelic therapies amid today’s mental health crisis. Nearly all forms of research being done on psychedelics are via the digestive tract, which slows uptake, requires higher dosage, and may lead to harmful side effects in the body.
“By leveraging nanoparticle encapsulation, Psycheceutical will overcome these limitations. Psycheceutical aims to provide similar nanoparticle-based solutions to any and all companies doing psychedelic drug development research.”
The second system, NeuroDirect™, enables the direct administration of neuroactive compounds to nerve connections to the brain, bypassing the blood-brain-barrier.
This enables smaller doses, improved efficacy of the active compound, and immediate response, as well as eliminating potentially toxic effects. This delivery method also removes the hallucinogenic effects of the compounds.
Removing the psychedelic experience
Psycheceutical says the delivery systems’ ability to eliminate the hallucinogenic effects of psychedelic medicines will facilitate wider medical adoption and use.
NeuroDirect™ technology developer, Dr Aung Din, said: “Having practiced neurology and neuropsychiatry for 30 years and been involved in clinical research to bring numerous drugs through the FDA to market, I am particularly excited about Psycheceutical’s work to deliver potentially harmful psychedelics in a safe way for medical purposes.
“The ability to avoid the systemic side effects of psychedelic compounds, such as nausea, dizziness, and disorientation, opens up a whole new world to neuro-therapeutics.”
“Combining the patented technologies of the Janus particle solution with the NeuroDirect™ delivery system solves the problem most psychedelic drug development companies are targeting: a safe, effective, take-at-home drug. The stronger the medicine, the more likely the need for on-site medical oversight; this layers in massive costs. NeuroDirect delivery, by eliminating toxicity and hallucinogenic properties, solves that problem,” said Chad Harman, CEO of Psycheceutical.
“The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. These breakthrough technologies that allow psychedelic compounds to be delivered in a safer and more effective way are a revolution for the entire psychedelic industry.”
Zappy Zapolin, Psycheceutical chief visionary officer, said: “My unique experience, access, and understanding of the psychedelic industry gives our company, Psycheceutical, a strategic advantage in targeting and acquiring valuable intellectual property and talent flying under the radar of other players in the space.
“Looking at the industry as it is growing, we are seeing the emergence of a brand-new sector: the psycheceutical industry, which merges the best of psychedelics and the best of pharmaceuticals. Psycheceutical is on a mission to bring safety and efficacy to psychedelic compounds with patented delivery systems designed specifically for this new class of medications.”
